WXIBF (WuXi Biologics (Cayman)) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 04, 2026)


WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.68
GF Value $4.77
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2026-07-04), WuXi Biologics (Cayman)'s Predictability Rank is 3.5-Stars. WuXi Biologics (Cayman)'s intrinsic value calculated from the Discounted Dividend model is $5.84 and current share price is $4.68. Consequently,

WuXi Biologics (Cayman)'s Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is N/A.

WXIBF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman) Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Margin of Safety % (DCF Dividends Based) falls into.


WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Margin of Safety % (DCF Dividends Based) Calculation

WuXi Biologics (Cayman)'s Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)=(Intrinsic Value: DCF (Dividends Based)-Current Price)/Intrinsic Value: DCF (Dividends Based)
=(0.00-4.68)/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.68 is trading 1.9% below its estimated GF Value™ of $4.77. GuruFocus considers WuXi Biologics (Cayman) to be Fairly Valued.

Key valuation signals for WXIBF:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $4.77 vs. price of $4.68 (1.9% below fair value)
  • GF Score™: 97/100 with 3 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.68
Price
$4.77
GF Value